Assorted News from the Last Week: AACR issued a Special Edition Advocacy Alert for National Cancer Survivor Month, with several pediatric-focused articles. Children’s brain tumors

Assorted News from the Last Week: The FDA has granted rare pediatric disease designation and orphan drug designation to FL118 for the treatment of patients

Assorted News from the Last Week: Black pediatric AML patients had more than twice the risk of acute kidney injury during treatment as their White

Assorted News from the Last Week: Childhood cancer from a parent’s point of view. U.S. Rep. Debbie Wasserman Schultz (FL-25), Rep. Brian Fitzpatrick(PA-1), Rep. Mark

Assorted News from the Last Week: CAC2 Supporting Organizations Day One and Servier completed enrollment in pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a

Assorted News from the Last Week: A pioneering trial from Cancer Grand Challenges team NexTGen will test CAR-T cell therapies designed from CAC2 Supporting Organization

Assorted News from the Last Week: CAC2 Supporting Organization Day One Biopharmaceuticals announced that Ibsen was awarded conditional marketing authorization for tovorafenib for children with

Assorted News from the Last Week: New clinical trials open: Beat Childhood Cancer Research Consortium will evaluate whether the drug eflornithine (DFMO) can help prevent

Assorted News from the Last Week: The ARPA-H Pediatric Care eXpansion (PCX) initiative is a $50 million program launched in January 2026 to create a

Assorted News from the Last Week: CAC2 Individual Member Laura DeKraker Lang-Ree provides a crucial look at self-advocacy for children and families with cancer in